

Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites

William Devine,[†] Sarah M. Thomas,[‡] Jessey Erath,^{||} Kelly A. Bachovchin,[†] Patricia J. Lee,[⊥] Susan E. Leed,[⊥] Ana Rodriguez,^{§,||} Richard J. Sciotti,[⊥] Kojo Mensa-Wilmot,[‡] and Michael P. Pollastri^{*,†,Ⓛ}

[†]Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States

[‡]Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, United States

[§]Department of Microbiology, Division of Parasitology, New York University School of Medicine, 341 East 25th Street New York, New York 10010, United States


^{||}Anti-Infectives Screening Core, New York University School of Medicine, New York, New York 10010, United States

[⊥]Experimental Therapeutics, Walter Reed Army Institute for Research, 2460 Linden Lane, Silver Spring, Maryland 20910, United States

S Supporting Information

ABSTRACT: Human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis present a significant burden across the developing world. Existing therapeutics for these protozoal neglected tropical diseases suffer from severe side effects and toxicity. Previously, NEU-1045 (**3**) was identified as a promising lead with cross-pathogen activity, though it possessed poor physicochemical properties. We have designed a library of analogues with improved calculated physicochemical properties built on the quinoline scaffold of **3** incorporating small, polar aminoheterocycles in place of the 4-(3-fluorobenzyloxy)aniline substituent. We report the biological activity of these inhibitors against *Trypanosoma brucei* (HAT), *T. cruzi* (Chagas disease), and *Leishmania major* (cutaneous leishmaniasis) and describe the identification of *N*-(5-chloropyrimidin-2-yl)-6-(4-(morpholinosulfonyl)phenyl)quinolin-4-amine (**13t**) as a promising inhibitor of *L. major* proliferation and 6-(4-(morpholinosulfonyl)phenyl)-*N*-(pyrimidin-4-yl)quinolin-4-amine (**13j**), a potent inhibitor of *T. brucei* proliferation with improved drug-like properties.

KEYWORDS: Antiparasitic agents, *Trypanosoma brucei*, *Trypanosoma cruzi*, *Leishmania major*, *Plasmodium falciparum*, Chagas disease, leishmaniasis, human African trypanosomiasis



Taken together, human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis are responsible for 4.4 million disability adjusted life years (DALY) and 70,000 deaths annually.¹ Caused by the protozoan parasites *Trypanosoma brucei*, *T. cruzi*, and *Leishmania* spp., respectively, these diseases are spread through insect vectors across Latin America, Africa, and parts of southern Asia.^{2–6} Current therapeutics suffer from severe side effects, complex and prolonged dosing regimens, high costs, and emerging resistance necessitating the need for new treatments.^{7–12}

Our group has reported the discovery of the antitrypanosomal activity of a library of compounds derived from a known tyrosine kinase inhibitor, lapatinib (**1**, Figure 1).^{13–16} Owing to the high degree of homology in kinetoplastid protein kinases (PKs) in *T. brucei*, *T. cruzi*, and *L. major*,¹⁷ we expected these compounds to be active against other trypanosomatid parasites. Thus, we tested new compounds against cultures of *T. brucei*, *T. cruzi*, and *L. major*. We also included *Plasmodium falciparum*, the causative agent of malaria, in this work. We identified two promising compounds as new leads for leishmaniasis, NEU-554 (**2**) and

NEU-1045 (**3**, Figure 1), which were evolved from the highly potent inhibitor of *T. brucei* growth, NEU-617 (**4**).¹⁴ Physicochemical analysis of this collection of compounds revealed they generally showed poor drug-like properties (Figure 1 and Table 1), and subsequent efforts have been focused on the development of new analogues aimed at improving these properties and overall lead quality (as described by lipophilic ligand efficiency (LLE))¹⁸ while maintaining or improving *in vitro* activity against the parasites. Consistent with our practice, we tested compounds against multiple kinetoplastid parasites in parallel. The results of these efforts are reported herein.

The broad spectrum antitrypanosomal activity of **3** attracted our attention as a modestly potent lead for HAT, Chagas disease, and leishmaniasis. The primary shortcoming of **3** is in its poor predicted physicochemical properties, driven by a high molecular weight (569.6 g/mol) and clogP (5.76). Much of

Received: January 9, 2017

Accepted: February 5, 2017

Published: February 5, 2017




Figure 1. SAR development of NEU-1045 from lapatinib.

Table 1. Druglike Properties of 3

	3	goal
molecular weight	569.6	≤500
clogP	5.76	≤5
protein binding (% free)	<0.03	>10
aqueous solubility (μM)	2	>50
human liver microsomes median CL _{int} (μL/min/mg)	98	<47
male rat hepatocytes median CL _{int} (μL/min/10 ⁶ cells)	19	<27

the MW and clogP of 3 may be attributed to the large, lipophilic 4-(3-fluorobenzoyloxy)aniline “head group”. We had previously observed that truncation of the similar 4-benzoyloxy-3-chloroaniline group in our quinazoline series led only to a 3-fold loss in activity (cf. NEU-369, 5 versus NEU-555, 6, Figure 2).¹⁴ Replacement of the 3-fluorobenzyl group with a methyl led to significant reductions in heavy atom count (Δ HAC = -7) and lipophilicity (Δ clogP = -1.87), giving rise to a similar ligand efficiency (LE = pEC₅₀/heavy atom count, 0.14 → 0.15) and improved LLE (pEC₅₀ - clogP, -0.43 → 0.93).^{18–21}

While the SAR of compounds built on the quinazoline scaffold were well explored¹³ little attention had to this point been given to compounds built on the quinoline scaffold, despite their widespread prevalence as a privileged scaffold in medicinal chemistry.^{22–24} When tested in a cross-parasite screening campaign, 3 inhibited *T. brucei*, *T. cruzi*, and *L. major* proliferation with good potency (*T. brucei* EC₅₀ = 0.37 μM; *T. cruzi* EC₅₀ = 2.8 μM; *L. major* EC₅₀ = 1.2 μM). We believed that




Figure 2. Truncation of lipophilic groups with partial retention of potency. All *L. major* data are in the intracellular amastigote life stage.

reducing the molecular size and lipophilicity would lead to an improvement in the overall ADME profile of the series. As such, we hypothesized that smaller, more polar analogues built upon the 3 scaffold could lead to compounds that maintained antiparasite activity and were more soluble in water.

In order to accomplish our goal, we enumerated a virtual library of analogues by using JChem Reactor (ChemAxon, Inc.) and a set of 246 heterocyclic amines that are commercially available in preweighed quantities. Using Vortex (Dotmatics, Inc.) we shaped the library on the basis of clogP (<5) and molecular weight (<500). From this filtered virtual library of 132 compounds, we selected 23 analogues for synthesis via inspection, eliminating compounds with multiple reactive moieties, or those with anticipated difficulties in chemical stability or purification. Also selected for synthesis was the quinoline analogue of 6, bearing the truncated 3-chloro-4-methoxyaniline group that was featured in the active truncated analogues of 1 and 4. Calculated physicochemical properties of these compounds in comparison with the properties of compounds previously described are plotted in Figure 3.^{13,14}






Figure 3. Physicochemical properties analysis of lapatinib analogues selected after *in silico* enumeration and filtering. Related compounds that were previously disclosed are shown in red,^{13,14} and the new shaped virtual library is shown in green. Compound 3 is shown in orange, and 6 is shown in blue.

The synthesis of our selected library commenced with generation of the sulfonamide 8 from 4-bromophenylsulfonyl chloride, 7 (Scheme 1). Halogen-lithium exchange of 8 followed by quenching with triisopropyl borate, and subsequent hydrolysis yielded boronic acid 9.

Suzuki-Miyaura coupling of 9 and 10¹⁴ produced 6-arylquinolinone 11 (Scheme 2). Deoxychlorination of 11

Scheme 1. NEU-1045 Analogue Western Half Synthesis^a

^aReagents and conditions: (a) morpholine, THF, rt, o.n.; (b) *n*-BuLi, THF, -78 °C, 1 h; B(O*i*-Pr)₃, rt, o.n.; HCl rt.

Scheme 2. NEU-1045 Analogue Synthesis^a

^aReagents and conditions: (a) 9, Et₃N, Pd(PPh₃)₂Cl₂, 1:1 EtOH/H₂O, ↓↑, 2 h; (b) POCl₃, ↓↑, 2 h; (c) TsOH, ArNH₂, DMSO, 80 °C, 24 h; (d) ArNH₂, Cs₂CO₃, Pd₂(dba)₃, xantphos, N₂, 1,4-dioxane, ↓↑, 24 h; (e) ArNH₂, KO*t*-Bu, Pd₂(dba)₃, xantphos, N₂, 1,4-dioxane, ↓↑, 24 h; (f) ArNH₂, NaH, 2:1 1,4-dioxane/DMF, 0 → 100 °C, 1 h.

generated **12** in nearly quantitative yield. Conversion to the corresponding 4-aminoquinolines **13a–z** could be achieved under acidic or basic conditions or via Buchwald–Hartwig amination.

Compounds were tested in an *in vitro* assay of RAW 264.7 macrophages infected with intracellular amastigotes of *L. major*, 3T3 fibroblasts infected with intracellular amastigotes of *T. cruzi*, and bloodstream form of *T. brucei*. The data are summarized in Table 2. All compounds synthesized were also screened against *P. falciparum*, the causative agent of malaria (Table S1, Supporting Information). Compound toxicity to mammalian cells was assessed against HepG2 cells as well as NIH 3T3 cells (Table S1).

All analogues possessing a thiazole, isothiazole, or thiadiazole (**13l–p**) consistently maintained anti-leishmanial activity in the single digit micromolar range (1.2–5.4 μM). Compound **13v**, incorporating the truncated aniline of **6**, and the isostere **13k** also displayed activity in this range. The incorporation of nitrogen atom(s) into six-membered arenes was poorly tolerated against *L. major* amastigotes, with the exception of **13f** (EC₅₀ = 5.8 μM) and **13t** (EC₅₀ = 0.37 μM).

Compound **13t** is of particular interest as the only compound in this library to achieve submicromolar activity against *L. major* amastigotes. Compound **13y**, devoid of an aminoheterocycle was inactive against all parasites tested, implicating these groups are essential structural motifs for antiparasitic activity. All compounds in this set were found to possess low host cell toxicity against HepG2 (TC₅₀ > 20 μM) except for **13k** (TC₅₀ = 9.0 μM).

Highlighted by **13t**, a dramatic improvement in LLE was achieved in this series (**13t** LLE = 3.02, compared to **3**, LLE = 0.16) driven by the reduced clogP (**13t** = 3.41, **3** = 5.76; Table S2, Supporting Information). Despite the improved lipophilicity profile, aqueous solubility (1 μM) and PPB (99.6%) remained poor. Taken together, these properties limited these compounds' progression to further studies against *Leishmania*.

Noting that the targeted potency range for anti-*T. cruzi* lead compounds is <10 μM,²⁵ we were pleased to observe that approximately half of the compounds tested showed some activity against *T. cruzi*, with six in the single-digit micromolar range. The most potent were **13k** (EC₅₀ = 3.6 μM) and **13o** (EC₅₀ = 3.9 μM). Importantly, we observed all compounds were nontoxic to NIH 3T3 host cells (TC₅₀ > 20 μM) with the exception of **13k** (TC₅₀ = 15 μM).

Table 2. Anti-Kinetoplastid Activity of Analogues of Compound 3

Cmpd	R	L. major		T. b. brucei		T. cruzi	
		EC ₅₀ (μM) ^{a,c}	LLE	EC ₅₀ (μM) ^b	LLE	EC ₅₀ (μM) ^b	LLE
3		1.2	0.16	0.37 ^c	0.67	2.8 ^d	-0.21
13a		7.1	1.1	0.98	2.0	6.2	1.2
13b		>20		4.5	1.9	16	1.4
13c		>20		3.8	2.6	>20	
13d		>20		16	1.5	>20	
13e		>20		6.6	2.4	>20	
13f		5.8	1.9	3.2	2.1	>20	
13g		>20		5.6	2.6	>20	
13h		>20		>20		>20	
13i		>20		2.5	2.7	>20	
13j		>20		0.024	4.9	>20	
13k		5.7	0.83	0.31	2.1	3.6	1.0
13l		3.1	2.2	4.2	2.0	>20	
13m		1.2	1.9	1.6	1.8	6.1	1.2
13n		2.0	2.3	4.7	1.9	>20	
13o		4.5	2.0	0.072	3.8	3.9	2.1
13p		5.4	2.4	1.2	3.0	>20	
13q		>20		>20		>20	
13r		>20		2.0	2.7	>20	
13s		>20		7.9	2.7	>20	
13t		0.37	3.0	3.8	2.0	>20	
13u		>20		0.11	4.1	>20	
13v		5.3	0.78	1.7	1.3	7.2	0.64
13w		>20		3.1	3.4	>20	
13x		>20		1.1	3.3	7.6	2.5
13y*	H	>20		>20		>20	
13z*		>20		0.71	3.4	>20	

^aAll *r*² values >0.75. ^bAll SEM values within 25%. ^c*n* = 1. ^d*n* = 2. ^{*}Isolated as a side product.

Sixteen analogues showed activity in the 1–10 μM range against *T. brucei*, and an additional six were $<1 \mu\text{M}$, including the highly active **13o** ($\text{EC}_{50} = 72 \text{ nM}$) and **13j** ($\text{EC}_{50} = 24 \text{ nM}$). We were intrigued by the activity of **13j** against *T. brucei*. Compared to **3**, **13j** has a lower molecular weight (447.5 vs 569.6 g/mol) and clogP (2.72 vs 5.76; Table S2, Supporting Information), reflected in the improved LE (0.24) and excellent LLE (4.9). This compound showed an acceptable $\log D_{7.4}$ (3.3) and improvement in human plasma protein binding (95.6%), though the thermodynamic aqueous solubility remained poor (1.4 μM).

We note that, despite the similarity between the kinomes of the three kinetoplastid parasites, we see distinct differences in selectivity across species. There are some potential explanations for this. First, though homologous across pathogens, certain targets may not have similar essentiality. Second, there are potential confounding factors involved by virtue of the nature of the parasite (intra- versus extracellular), and there could be potentiating effects from host cell targets. We do note, however, that we do not know the target(s) of action for these compounds; this is of interest for future work.

Given the attractive potency and drug-like properties of **13j**, we performed pharmacokinetic experiments in mice. Compound **13j** was dosed by intraperitoneal injection to 18 female BALB/c mice at 10 mg/kg. Blood and brain samples were collected from groups of three at 0.08, 0.25, 1, 4, 8, and 24 h and analyzed by LC–MS/MS. The results are visualized in Figure S1 and tabulated in Tables S3–S6 in the Supporting Information. We observed plasma exposure >120 -fold of the EC_{50} for 4 h, and the maximum brain to plasma ratio was 0.01 at 0.25 h after dosing **13j**. In conjunction with the low levels of **13j** in the brain, we noted the rapid clearance in human liver microsomes ($\text{Cl}_{\text{int}} = 207.5 \mu\text{L}/\text{min}/\text{mg}$) and rat hepatocytes ($\text{Cl}_{\text{int}} = 31.5 \mu\text{L}/\text{min}/10^6 \text{ cells}$) suggested **13j** would show poor efficacy in *in vivo* models of infection. We continue to work toward compounds with improved PK properties and will report these results in due course.

In summary, through a strategy of generation and filtering of a virtual library of analogues of **3** on the basis of computed physicochemical properties, we have identified potent inhibitors of *L. major*, *T. cruzi*, and *T. brucei* proliferation. These compounds possess improved drug-like properties and efficiency metrics as a result, in part, of the reduction in molecular weight and lipophilicity designed in the virtual library. Further work aimed at improving the *in vivo* ADME properties and requisite properties for the different protozoan parasites will be undertaken. In addition, attention must be paid to the nonparallel SAR that we have observed between parasites. As a result, a single, multipathogen-targeting agent would seem unlikely, and pathogen-specific optimization is needed at this point.

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmchemlett.7b00011.

Chemical synthesis and characterization of new compounds reported, antimalarial and physicochemical property data tables (annotated with NEU registry numbers), and biological methods (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: m.pollastri@neu.edu. Tel: 617-373-2703.

ORCID

Michael P. Pollastri: 0000-0001-9943-7197

Funding

Funding from the National Institutes of Health (R01AI124046 and R56AI099476 to M.P.P. and K.M.-W.) and Northeastern University are gratefully acknowledged.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

ChemAxon is gratefully acknowledged for the free academic license provided for their software suite. Dr. Lori Ferrins is gratefully acknowledged for her assistance in preparing this manuscript. We are grateful to AstraZeneca for the determination of *in vitro* ADME properties in support of this work.

■ REFERENCES

- (1) Moran, M.; Guzman, J.; Ropars, A.-L.; McDonald, A.; Jameson, N.; Omune, B.; Ryan, S.; Wu, L. Neglected Disease Research and Development: How Much Are We Really Spending? *PLOS Med.* **2009**, *6*, e1000030.
- (2) World Health Organization. Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected tropical diseases; 2015.
- (3) Simarro, P. P.; Cecchi, G.; Franco, J. R.; Paone, M.; Diarra, A.; Ruiz-Postigo, J. A.; Fevre, E. M.; Mattioli, R. C.; Jannin, J. G. Estimating and mapping the population at risk of sleeping sickness. *PLoS Neglected Trop. Dis.* **2012**, *6*, e1859.
- (4) Alvar, J.; Velez, I. D.; Bern, C.; Herrero, M.; Desjeux, P.; Cano, J.; Jannin, J.; den Boer, M.; Team, W. H. O. L. C. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* **2012**, *7*, e35671.
- (5) de Souza, A.; Ishikawa, E.; Braga, R.; Silveira, F.; Lainson, R.; Shaw, J. Psychodopygus complexus, a new vector of Leishmania braziliensis to humans in Para State, Brazil. *Trans. R. Soc. Trop. Med. Hyg.* **1996**, *90*, 112–113.
- (6) Andrade, L. O.; Andrews, N. W. The Trypanosoma cruzi-host-cell interplay: location, invasion, retention. *Nat. Rev. Microbiol.* **2005**, *3*, 819–823.
- (7) Chulay, J. D.; Spencer, H. C.; Mugambi, M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). *Am. J. Trop. Med. Hyg.* **1985**, *34*, 702–709.
- (8) Delgado, J.; Macias, J.; Pineda, J. A.; Corzo, J. E.; Gonzalez-Moreno, M. P.; de la Rosa, R.; Sanchez-Quijano, A.; Leal, M.; Lissen, E. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. *Am. J. Trop. Med. Hyg.* **1999**, *61*, 766–769.
- (9) Herwaldt, B. L.; Berman, J. D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. *Am. J. Trop. Med. Hyg.* **1992**, *46*, 296–306.
- (10) Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat. Rev. Microbiol.* **2007**, *5*, 873–882.
- (11) Maltezos, H. C. Drug resistance in visceral leishmaniasis. *J. Biomed. Biotechnol.* **2010**, *2010*, 617521.
- (12) Messori, A.; Fadda, V.; Maratea, D.; Trippoli, S.; Marinai, C. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis. *Clin. Infect. Dis.* **2013**, *57*, 1783–1784.
- (13) Patel, G.; Karver, C. E.; Behera, R.; Guyett, P. J.; Sullenberger, C.; Edwards, P.; Roncal, N. E.; Mensa-Wilmot, K.; Pollastri, M. P. Kinase scaffold repurposing for neglected disease drug discovery: discovery of

an efficacious, lapatinib-derived lead compound for trypanosomiasis. *J. Med. Chem.* **2013**, *56*, 3820–3832.

(14) Devine, W.; Woodring, J. L.; Swaminathan, U.; Amata, E.; Patel, G.; Erath, J.; Roncal, N. E.; Lee, P. J.; Leed, S. E.; Rodriguez, A.; Mensa-Wilmot, K.; Sciotti, R. J.; Pollastri, M. P. Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery. *J. Med. Chem.* **2015**, *58*, 5522–5537.

(15) Katiyar, S.; Kufareva, I.; Behera, R.; Thomas, S. M.; Ogata, Y.; Pollastri, M.; Abagyan, R.; Mensa-Wilmot, K. Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds. *PLoS One* **2013**, *8*, e56150.

(16) Lackey, K. E. Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor. *Curr. Top. Med. Chem.* **2006**, *6*, 435–460.

(17) Parsons, M.; Worthey, E. A.; Ward, P. N.; Mottram, J. C. Comparative analysis of the kinomes of three pathogenic trypanosomatids: *Leishmania major*, *Trypanosoma brucei* and *Trypanosoma cruzi*. *BMC Genomics* **2005**, *6*, 1–19.

(18) Shultz, M. D.; Cheung, A. K.; Kirby, C. A.; Firestone, B.; Fan, J.; Chen, C. H.; Chen, Z.; Chin, D. N.; Dipietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.; Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.; Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.; Tomlinson, R. C.; Toure, B. B.; Visser, M.; Wang, R. M.; Waters, N. J.; Shao, W. Identification of NVP-TNKS656: The Use of Structure-Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor. *J. Med. Chem.* **2013**, *56*, 6495–6511.

(19) Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. *Drug Discovery Today* **2004**, *9*, 430–431.

(20) Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96*, 9997–10002.

(21) Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. *Nat. Rev. Drug Discovery* **2007**, *6*, 881–890.

(22) Zhao, H.; Dietrich, J. Privileged scaffolds in lead generation. *Expert Opin. Drug Discovery* **2015**, *10*, 781–790.

(23) Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Privileged scaffolds for library design and drug discovery. *Curr. Opin. Chem. Biol.* **2010**, *14*, 347–361.

(24) Bongarzone, S.; Bolognesi, M. L. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. *Expert Opin. Drug Discovery* **2011**, *6*, 251–268.

(25) Katsuno, K.; Burrows, J. N.; Duncan, K.; van Huijsduijnen, R. H.; Kaneko, T.; Kita, K.; Mowbray, C. E.; Schmatz, D.; Warner, P.; Slingsby, B. T. Hit and lead criteria in drug discovery for infectious diseases of the developing world. *Nat. Rev. Drug Discovery* **2015**, *14*, 751–758.